Explore studies of cjc 1295.
Postmenopausal women, even with estradiol replacement, showed reduced fasting GH, IGF-1, and diminished dual-secretagogue GH burst response compared to premenopausal women — suggesting irreversible menopausal GH axis changes.
Erickson, Dana; Keenan, Daniel M; Mielke, Kristi; Bradford, Kandace; Bowers, Cyril Y; Miles, John M; Veldhuis, Johannes D · Clinical Trial
In-vitro GHRP-2 treatment altered pituitary somatotroph expression of GH, Pit-1 transcription factor, GHRH-R, and GHS-R at mRNA and protein levels, demonstrating GH secretagogue-induced pituitary cell reprogramming for enhanced GH-axis responsiveness.
Yan, Ming; Hernandez, Maria; Xu, Ruwei; Chen, Chen · In Vitro
CJC-1295 (long-acting GHRH analog with extended half-life through DPP-IV resistance) normalized pulsatile GH secretion and IGF-1 in GH-deficient rats with once-daily SC administration — practical sustained GH-axis restoration for potential clinical simplification.
Alba, Maria; Fintini, Danilo; Sagazio, Alessia; Lawrence, Betty; Castaigne, Jean-Paul; Frohman, Lawrence A; Salvatori, Roberto · Animal Study
Single SC injection of CJC-1295 maintained elevated pulsatile GH secretion and IGF-1 for days in healthy subjects, with dose-dependent duration of action — validating once-weekly (or less) dosing for sustained GH-axis restoration in the first human clinical trial.
Ionescu, Madalina; Frohman, Lawrence A · Clinical Trial
Single SC CJC-1295 injection in healthy adults produced dose-dependent sustained GH pulsatility and IGF-1 elevation lasting 6-14 days depending on dose, with 2-3 fold IGF-1 increase maintained for up to 2 weeks — the most sustained GH-axis restoration from a single peptide dose.
Teichman, Sam L; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A · RCT
GHRH demonstrated agonist activity at the GHS-R1a (ghrelin receptor) at physiologically relevant concentrations, revealing previously unknown cross-talk between the GHRH and ghrelin receptor systems — explaining some synergistic GH-releasing effects.
Casanueva, Felipe F; Camiña, Jesus P; Carreira, Marcos C; Pazos, Yolanda; Varga, Jozsef L; Schally, Andrew V · In Vitro
Optimized magnetic bead immunopurification coupled with LC-HRMS achieved a limit of detection of 0.2 ng/mL and limit of identification of 0.5 ng/mL for GHRH analogues in human urine, with acceptable precision and specificity.
Pont, Laura; Alechaga, Élida; Terrero, Alejandro; Monfort, Núria; Ventura, Rosa · Methodology